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Abstract: Clinically-related basic studies on the behavioral effects of ribavirin treatment are still lacking despite its wide use 
as an antiviral medication. This paper considers the effects of low ribavirin doses (10, 20 and 30 mg/kg/day) on psychomo-
tor activity (novelty-induced exploratory behavior, d-amphetamine (AMPH, 1.5 mg/kg, intraperitoneal)-induced motor 
activity), and body weight gain in socially undisturbed adult male Wistar rats 24 h after the first, seventh and fourteenth 
once-a-day injection. Low doses of ribavirin were tested in an attempt to avoid the recognized systemic side effects related 
to high-dose usage. None of the singly applied ribavirin doses affected exploratory/spontaneous and AMPH-induced 
motor behavior (locomotion, stereotypy-like and vertical activity), however, body weight gain was significantly lower after 
treatment with 30 mg/kg of ribavirin. The 7- and 14-day treatments with 10 and 30 mg/kg/day of ribavirin significantly 
suppressed novelty-induced locomotion and body weight gain; the 14-day treatment with ribavirin at a dose of 30 mg/kg/
day decreased AMPH-induced stereotypy. These findings indicate that repeated application (up to 14 days) of low ribavirin 
doses results in low novelty-induced locomotion along with reduced weight gain, accentuating the existence of a U-shaped 
dose-response relationship with a prolonged duration of ribavirin treatment.
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INTRODUCTION
Ribavirin (Virazole, 1-β-D-ribofuranosyl-1,2,4-triazole-
3-carboxamide) is a well-known C-nucleoside analogue 
that has been investigated as a therapy for numerous 
viral infections, such are influenza A, B and C, herpes 
simplex, hepatitis C, hemorrhagic fever, Coxsackie, 
Lassa, Dengue, Hantaan, West Nile viruses, etc. [1]. 
It is mainly used for treating chronic hepatitis C vi-
rus (HCV) infection, especially in combination with 
interferon alpha [2]. According to medical reports, in 
addition to the therapeutic objective, side effects are 
often associated with standard therapy. Some of these 
side effects include depression, anxiety, psychosis, 
cognitive impairment and body weight (BW) loss 
[3-6]. The exact contributions of each component of 
combined therapy to the side effects have not been 
elucidated, but there is a view that they are mainly 
related to interferon alpha [7-10]. Adequate expo-
sure to ribavirin seems crucial for achieving the best 
virological response and up to now, anemia has been 
reported as a frequent dose-dependent limiting side 
effect of ribavirin use [11].
The delivery of ribavirin to the central nervous 
system (CNS) still poses a challenge due to its low 
penetration of the blood-brain barrier (BBB) [12,13]. 
Nevertheless, there are clear indications about its brain 
distribution following different routes of administra-
tion and its affinity for and activation of adenosine 
A1 receptors [14,15]. Previous findings showed that 
in the brain of commonly used experimental animals, 
A1 receptors were concentrated in the hippocampus, 
the cerebral cortex, some thalamic nuclei, the basal 
ganglia and the cerebellar cortex [16]. The role of 
adenosine receptors in the regulation of behavior has 
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been elucidated, indicating that the receptor subtype-
specific interactions between adenosine and dopamine 
receptors (A1/D1 and A2A/D2) play an essential role 
in the modulation of basal ganglia function [17]. At the 
behavioral level, adenosine receptor agonists inhibit 
and adenosine receptor antagonists potentiate the 
motor-activating effects of dopamine agonists [18,19]. 
In that context, our previous experiments showed 
that the intraperitoneal (i.p.) injection of ribavirin, 
acutely applied at doses of 20 and 30 mg/kg, decreased 
locomotor activity in rats induced by amphetamine 
(AMPH; 1.5 mg/kg, i.p.) [20]. Considering the well-
known fact that nucleus accumbens (NAc) dopamine 
mediates AMPH-induced rewarding and locomotor 
stimulating effects [21], these findings accentuated the 
central effects of i.p. administered ribavirin. Neverthe-
less, clinically-related basic studies on the behavioral 
consequences of chronic ribavirin treatment with 
respect to the central regulation of motor behavior 
[19] are still lacking. Importantly, it has been shown 
that chronic treatment with agents acting at adenos-
ine A1 receptors results in behavioral effects that are 
significantly different from those observed following 
their acute administration [22-24].
Drugs with psychoactive capacity produce their 
effects on behavior, affective and sensory perceptual 
functions because of their ability to bind to specific 
sites in the CNS (and thereby to modify ongoing neu-
ronal processes); regardless of the fact that for a given 
substance we do not know the specific mechanism(s) 
of action, behavioral changes in certain experimental 
paradigms are confirmation that the treatment is act-
ing. Therefore, any medication that disrupts the highly 
interconnected circuits normally serving to process 
the stream of stimuli detected by our brains from the 
outside world has the capacity to produce psychomotor 
changes [25]. It is known that the response to novelty 
is very complex and that it reflects a desire to explore 
novelty, novelty-related anxiety and, with regard to the 
time-dependent profile of the activity, adaptability to 
the certain environment [26]. New findings indicate 
that psychomotor activity observation can serve as a 
potential objective tool capable of monitoring the course 
of affective states in everyday life [27]. Although it may 
sound incidental, the dynamics of the psychomotor 
response to a novel environment should not be under-
estimated. In neurologically intact rats, locomotor and 
vertical activities reflect exploratory activity and are 
also used as an index of psychomotor activation after 
exposure to low doses of psychostimulant drugs [28].
Having in mind that ribavirin is still recognized 
as an elusive drug [29], and considering all the above-
mentioned, it is of particular importance to clarify 
the neurobehavioral effects of ribavirin application. 
To improve current knowledge in the field, this study 
focused on investigating the effect of low ribavirin 
doses (10, 20 and 30 mg/kg/day, i.p.; single or re-
peated once-a-day administration) on novelty-induced 
[30,31] and AMPH-induced psychomotor activity 
[21], and on BW gain (as an indicator of energetic 
intake in the conditions of controlled utilization [5]) 
in socially undisturbed adult male rats. Common to 
psychomotor activation and the motivational aspect 
of food intake is that they are highly dependent on 
mesolimbic dopaminergic transmission [21,30-32]. 
Low doses of ribavirin were tested in an attempt to 
avoid the already recognized side effects related to its 
usage at high doses [33,34].
MATERIALS AND METHODS
Animals and drugs
Male Wistar 2.5-3.5-month-old rats were used. The 
animals were maintained in groups of 4-5 rats per 
cage under standard conditions (23±2°C, 60-70% 
relative humidity, 12 h light/dark intervals, food and 
water provided ad libitum). All animal procedures 
were in compliance with Directive 2010/63/EU on the 
protection of animals used for experimental and other 
scientific purposes and were approved by the Ethical 
Committee for the Use of Laboratory Animals of the 
Institute for Biological Research “Siniša Stanković”, 
University of Belgrade, Serbia.
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-
carboxamide; Virazole) and d-amphetamine sulfate 
were acquired from ICN Pharmaceuticals, Costa Mesa, 
USA. Both substances were dissolved in saline (the dose 
of interest in 1.0 mL 0.9% NaCl) and i.p. injected (1 
mL per kg of BW). Dose translation, which provides 
conversion of the animal dose to a human dose and, 
after reversion, conversion of the human dose to an 
animal dose, is based on body surface area [35]. Thus, 
the daily doses of ribavirin used in our study on adult 
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rats (10, 20 and 30 mg/kg/day) corresponded to hu-
man daily doses of 1.6, 3.2, and 4.8 mg/kg/day, or to 
100, 200 and 300 mg/day, respectively (assumed for 
a 60 kg human). 
Behavioral measurement system and data 
preparation
The behavior of the animals was monitored in the open 
field by an automatic device (Columbus Auto-Track 
System, Version 3.0 A, Columbus Institute, OH, USA) in 
an isolated room under controlled conditions (described 
in detail in [20]). Different parameters, including 
locomotion (distance traveled in cm), stereotypy-like 
movements (such as sniffing, self-grooming, licking and 
head waving), and vertical activity or rearing (lifting 
both forepaws off the floor), were analyzed. The type 
of activity, characterized by the animal movements, 
was determined by the user-defined box size (set to 
5 beams). The described parameters were defined in 
accordance with the auto-track system for IBM-PC/
XT/AT version 3.0A (Instruction Manual 0113-005L, 
1990).
After registration, the data were prepared bearing 
in mind that when certain behavioral phenomena 
occurred only during a particular interval of a long 
registration period, the usage of long intervals could 
underestimate the behavior, as intervals during which 
certain behavioral changes occurred more frequently 
would be identified. We first read automatically re-
corded data at 10-min intervals within a 120-min 
registration period. Based on these findings, the data 
were further expressed as the total for three 40-min 
consecutive periods. Such a methodological approach, 
which is in accordance with the suggestion that the 
determination of interval length should not be arbitrary 
and based on convention but empirically determined 
for a particular behavioral paradigm [36], allowed for 
the detection of fundamental behavioral differences 
during particular intervals as well as an appropriate 
comparison between groups instead of averaging and 
mitigating changes. We strongly believe that this is im-
portant to note because with such findings as obtained 
in our study, different methods could be applied for 
data analysis and conclusions could differ depending 
on the selected method.
Experimental procedure
Two sets of experiments were performed to address the 
consequences of ribavirin administration on sponta-
neous motor behavior in the novel environment and 
BW gain (Experiment 1), as well as on AMPH-induced 
motor activity (Experiment 2) of adult male rats.
In Experiment 1 (a schematic presentation is given 
in Fig. 1A),  24 adult male rats were used. The cohort 
was divided into four groups (n=6 per group) and 
injected once a day with saline (0.9% NaCl; 1 mL/kg; 
control group) or ribavirin at doses of 10, 20 and 30 
mg/kg (i.p.) for 14 days. The body weight was measured 
every day before the treatment, i.e. between 15.00 and 
16.00 h. The animals’ behavior was, in addition to the 
baseline activity (day 0), repeatedly monitored across 
the experiment, precisely on days 2 and 8, as well as 
after termination of the treatment (day 15; Fig. 1A) 
between 09.00 and 15.00 h. The animals were placed 
in the open field arena and allowed to freely explore it 
for 120 min. This experimental procedure allowed us 
to study the influence of single or repeated exposures 
to ribavirin on novelty-induced exploratory activity, 
which is highly regulated by mesolimbic dopaminergic 
transmission [31].
In Experiment 2 (schematic presentation is given 
in Fig. 1B), 72 adult male rats were used. The cohort 
was divided into three sets (24 rats per each). The 
first, second and third sets of animals were exposed 
to a single and 7 and 14 treatments, respectively, with 
saline (0.9% NaCl; 1 mL/kg, i.p.; control group, n=6) 
or ribavirin at doses of 10, 20 and 30 mg/kg/day (i.p.) 
(n=6 per dose). The treatment was performed between 
15.00 and 16.00 h. The AMPH challenge (1.5 mg/kg, 
i.p.) was performed on the 2nd day (for the first set of 
animals), the 8th day (for the second set of animals), 
and on the 15th day (for the third set of animals) of 
the experiment. Immediately after the AMPH injec-
tion, the animals’ behavior was monitored in an open 
field arena for 120 min. This experimental procedure 
allowed us to study the influence of single or repeated 
exposures to ribavirin on AMPH-induced hyperactiv-
ity of animals and, as the AMPH acts as an indirect 
dopamine agonist [37], to indirectly assess ribavirin 
exposure-induced changes in the functioning of the 
dopaminergic system. Behavioral testing was performed 
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between 09.00 and 15.00 h. The BW was measured 
every day before the treatment (between 15.00 and 
16.00 h); the data obtained from the third set of animals 
(duration of the treatment was 14 consecutive days) 
were, in addition to the data obtained in Experiment 
1, used to calculate changes in BW gain (to obtain 
the total number of 12 animals per group 
with regard to this parameter). BW gain 
was calculated by subtracting the weight 
of the rat measured at the beginning of the 
experiment from that measured on the day 
of behavioral testing.
Statistical analysis
The Kolmogorov-Smirnov test was used 
to assess the normality of data sets. Some 
of the data did not have a normal distribu-
tion before and even after transformation. 
Therefore, Steel’s test (a non-parametric 
version of the Dunnett test; [38]) was used 
to determine which means differed from 
the control considering that several au-
thors suggested that errors in statistics can 
be prevented by carrying out direct com-
parisons with the control without subjecting 
the data to analysis of variance (ANOVA), 
especially when monotonicity between the 
dose and response is not assumed [39, 40]. 
Nevertheless, the Kruskal-Wallis ANOVA 
was performed as well, and the obtained 
findings are presented in Table 1. The Fried-
man ANOVA followed by the Wilcoxon 
matched-pairs test was used to analyze the 
timeline of changes in behavior and BW 
within each group. The accepted level of 
significance was p<0.05.
RESULTS
Exploratory activity of adult male rats 
in a novel environment after exposure 
to different doses of ribavirin – impact 
of treatment duration
Spontaneous activity of the animals in a 
novel environment after a single or repeated 
treatments with different doses of ribavirin is presented 
in Fig. 2. On day 0, all examined groups of rats showed 
very similar timeline profiles of locomotion (Fig. 
2A, first panel), stereotypy-like movements (Fig. 2B, 
first panel) and vertical activity (Fig. 2C, first panel), 
which justified their further use in the experiment. All 
Fig. 1. Schematic presentation of the experimental procedure. A – The influence of 
low ribavirin doses (10, 20 and 30 mg/kg/day, i.p., dissolved in saline as the dose of 
interest in 1.0 mL 0.9% NaCl) on spontaneous motor behavior in a novel environ-
ment was monitored in adult male Wistar rats. Testing was performed on days 2, 8 
and 15, i.e. a day after 1-, 7- and 14-day treatments. Control group received saline 
(1 mL/kg). The body weight (BW) was measured every day before the treatment. 
The baseline parameters were scored before the start of the treatment (day 0). The 
arrows above the timing line indicate the duration of the treatment (saline or speci-
fied dose of ribavirin); the arrows below the timing line indicate that the animal was 
taken (↓) from the home cage for testing and, after test completion, it was returned 
(↑) to continue the treatment. B – The influence of low ribavirin doses (10, 20 and 
30 mg/kg/day, i.p.) on d-amphetamine (AMPH, 1.5 mg/kg, i.p.)-induced motor 
behavior in the novel environment was monitored in adult male Wistar rats on 
days 2, 8 and 15, i.e. a day after the 1-, 7- and 14-day treatments. Upward-pointing 
arrows below the timing line indicate duration of the treatment (saline or one of 
three specified ribavirin doses), while the downward-oriented arrows indicate 
the day of the d-AMPH challenge and subsequent monitoring (after this step the 
animals were excluded from the experiment). The BW was measured every day 
before the treatment; the data obtained from the third set of animals (duration of 
the treatment was 14 consecutive days) were, in addition to the data obtained in the 
‘A’ part of the experiment, used to calculate changes in body weight gain (to obtain 
the total number of 12 animals per group regarding this parameter).
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examined motor activities were the highest 
during the first 40 min of registration and 
decreased thereafter (results of Friedman 
ANOVA and Wilcoxon test are given in 
Tables 2 and 3, respectively).
On day 2 (a day after the first once-
a-day i.p. injection of saline or specified 
doses of ribavirin), no significant changes 
in novelty-induced exploratory activity 
were detected in ribavirin groups compared 
to the control group (Fig. 2A-C, second 
panels). All groups of animals showed ex-
pected decreases in motor activities across 
the registration period, except animals that 
were injected ribavirin at a dose of 10 mg/
kg with regard to vertical activity (results 
of Friedman ANOVA and Wilcoxon test 
are given in Tables 2 and 3, respectively).
On day 8 (a day after the seventh once-a-
day i.p. injection of saline or specified doses 
of ribavirin), we detected highly similar 
novelty-induced motor activity in all groups 
of animals during the first and the last 40 
min of registration. During the second 40 
min, significant differences appeared in 
terms of decreased locomotion of animals 
exposed to 10 and 30 mg/kg/day of riba-
virin compared to control/saline-injected 
animals (Fig. 2A, third panel, *p<0.05, Steel’s 
test). At the same time interval, decreased 
stereotypy-like activity of animals exposed 
Table 1. Results of Kruskal-Wallis ANOVA
    Locomotion Stereotypy-like movements Vertical activity
  40 min 80 min 120 min 40 min 80 min 120 min 40 min 80 min 120 min
  H(3,24) p H(3,24) p H(3,24) p H(3,24) p H(3,24) p H(3,24) p H(3,24) p H(3,24) p H(3,24) p
SPONTANEOUS MOTOR BEHAVIOR
Baseline   0.08 0.99 0.31 0.96 4.97 0.17 0.67 0.88 1.19 0.76 6.35 0.10 0.27 0.96 2.65 0.45 3.73 0.29
2nd day   2.91 0.41 0.69 0.88 0.88 0.83 4.55 0.21 0.27 0.97 1.45 0.69 3.71 0.29 2.02 0.57 5.19 0.16
8th day   4.38 0.22 7.30 0.06 1.08 0.78 3.55 0.31 7.43 0.06 2.28 0.52 3.02 0.39 7.03 0.07 1.69 0.64
15th day   1.93 0.59 1.04 0.79 8.87 * 2.66 0.45 1.07 0.79 4.01 0.26 1.73 0.63 0.24 0.97 0.97 0.81
AMPH-INDUCED MOTOR BEHAVIOR
2nd day   3.63 0.30 4.03 0.26 1.42 0.70 1.71 0.63 2.46 0.48 0.77 0.86 1.82 0.61 3.01 0.39 1.74 0.63
8th day   1.57 0.67 4.01 0.26 2.26 0.52 1.54 0.67 7.85 * 5.57 0.13 2.19 0.53 0.93 0.82 1.57 0.67
15th day   1.99 0.58 2.81 0.42 0.62 0.89 2.69 0.44 2.65 0.45 8.39 * 1.29 0.73 3.69 0.30 1.21 0.75
*p<0.05; H(degrees of freedom, number of animals); d-amphetamine (AMPH)
Fig. 2. The influence of ribavirin applied at low doses (10, 20 and 30 mg/kg/day, 
i.p.) for 14 days on spontaneous locomotion (A), stereotypy-like activity (B) and 
vertical activity (C) of rats. The animals’ behavior was, in addition to the baseline 
activity (day 0), repeatedly monitored across the experiment, precisely on days 
2 and 8, as well as after termination of the treatment (day 15). The animals were 
placed in the open field arena and allowed to freely explore it for 120 min. Each 
time point represents the mean±SEM (n=6). *p<0.05 indicates significant differ-
ences compared to the control (saline-injected) group (Steel’s test).
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to 10 mg/kg/day of ribavirin (Fig. 2B, third panel, 
*p<0.05) and decreased vertical activity of animals 
exposed to 20 mg/kg/day of ribavirin compared to 
the control (Fig. 2C, third panel, *p<0.05) were also 
observed. In all groups of animals, Friedman ANOVA 
revealed a significant decrease in all examined motor 
activities across registration time (Table 2; post hoc 
analysis (Wilcoxon test) is given in Table 3).
On day 15 (a day after the fourteenth once-a-day 
i.p. injection of saline or specified doses of ribavirin), 
we detected highly similar novelty-induced motor ac-
tivity in all groups of animals during the first and the 
second 40 min of registration. During the third 40 min, 
significant differences appeared in terms of decreased 
locomotion of animals exposed to 10 and 30 mg/kg/day 
of ribavirin compared to the control (Fig. 2A, fourth 
panel, *p<0.05, Steel’s test), without significant changes 
in stereotypy-like and vertical activities (Figs. 2B and 
2C, respectively, fourth panels). Importantly, Friedman 
ANOVA revealed non-significant changes in stereotypy-
like and vertical activities across the registration time 
in the control group. In all groups exposed to ribavirin, 
the pattern of changes in the activities over time was 
preserved, except in the group exposed to 20 mg/kg/
day regarding vertical activity (results of Friedman 
ANOVA and Wilcoxon test are given in Tables 2 and 3, 
respectively). Appropriate findings of Kruskal-Wallis 
ANOVA regarding the exploratory activity of adult 
male rats in the novel environment after exposure to 
different doses of ribavirin are given in Table 1.
D-AMPH-induced motor activity of adult male 
rats after exposure to different doses of ribavirin 
– impact of treatment duration
On day 2 (a day after the first once-a-day i.p. injection 
of saline or specified doses of ribavirin), no signifi-
cant changes in AMPH-induced motor activity were 
detected in ribavirin groups compared to the control 
group (Figs. 3A-C, first panels). All groups of animals 
showed expected decreases in motor activities across 
the registration period, except animals that were in-
jected with ribavirin at a dose of 10 mg/kg with regard 
to vertical activity (results of Friedman ANOVA and 
Wilcoxon test are given in Tables 2 and 3, respectively).
On day 8 (a day after the seventh once-a-day i.p. 
injection of saline or specified doses of ribavirin), we 
recorded slight changes in d-AMPH-induced motor 
activity during the second 40 min of registration, but 
they were not statistically significant (Figs. 3A-C, second 
panels). In all groups of animals, Friedman ANOVA 
revealed a significant decrease in all examined motor 
activities across registration time (Table 2; post hoc 
analysis (Wilcoxon test) is given in Table 3).
On day 15 (a day after the fourteenth once-a-day 
i.p. injection of saline or specified doses of ribavirin), 
Table 2. Results of Friedman ANOVA
  Locomotion Stereotypy-like movements
Vertical 
activity
  χ2(6,2) p χ2(6,2) p χ2(6,2) p
Saline
Baseline 9.33 ** 10.33 ** 8.32 *
2nd day 9.00 * 9.33 ** 7.60 *
8th day 9.33 ** 9.33 ** 7.60 *
15th day 10.33 ** 5.33 0.07 5.20 0.07
Ribavirin 10 mg/kg/day
Baseline 9.33 ** 9.33 ** 8.44 *
2nd day 9.48 ** 7.00 * 3.89 0.14
8th day 9.00 * 9.00 * 9.00 *
15th day 9.00 * 9.33 ** 9.33 **
Ribavirin 20 mg/kg/day
Baseline 9.33 ** 9.33 ** 10.00 **
2nd day 9.33 ** 9.00 * 7.89 *
8th day 10.33 ** 10.33 ** 7.60 *
15th day 9.33 ** 9.33 ** 3.26 0.20
Ribavirin 30 mg/kg/day
Baseline 10.33 ** 10.33 ** 11.57 **
2nd day 9.33 ** 9.00 * 8.40 *
8th day 9.33 ** 10.33 ** 10.33 **
15th day 12.00 ** 12.00 ** 11.57 **
Saline + AMPH
2nd day 10.33 ** 10.33 ** 7.00 *
8th day 10.33 ** 11.57 ** 8.33 *
15th day 10.33 ** 4.33 0.11 7.00 *
Ribavirin 10 mg/kg/day + AMPH
2nd day 12.00 ** 10.33 ** 4.26 0.12
8th day 12.00 ** 10.33 ** 7.00 *
15th day 12.00 ** 12.00 ** 6.33 *
Ribavirin 20 mg/kg/day  + AMPH
2nd day 9.00 * 9.33 ** 9.58 **
8th day 12.00 ** 12.00 ** 9.33 **
15th day 8.33 * 12.00 ** 10.33 **
Ribavirin 30 mg/kg/day  + AMPH
2nd day 12.00 ** 10.33 ** 10.33 **
8th day 10.33 ** 12.00 ** 10.33 **
15th day 10.33 ** 12.00 ** 5.20 0.07
*p<0.05, **p<0.01; χ2(number of animals, degrees of freedom); d-amphetamine (AMPH)
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we recorded highly similar AMPH-induced motor 
activity in all groups of animals except the third 40 
min, when significant differences appeared in terms 
of decreased stereotypy-like activity of animals ex-
posed to 30 mg/kg/day of ribavirin, as compared to the 
saline-injected control (Fig. 3B, third panel, *p<0.05, 
Steel’s test). Importantly, Friedman ANOVA revealed 
non-significant changes in stereotypy-like activity 
across the registration time in the control group. In all 
groups exposed to ribavirin, the pattern of changes in 
the activities over the time was preserved, except in the 
group exposed to 30 mg/kg/day with regard to vertical 
activity (results of Friedman ANOVA and Wilcoxon 
test are given in Tables 2 and 3, respectively).
Appropriate findings of Kruskal-Wallis ANOVA 
regarding d-AMPH-induced motor activity of adult 
male rats after exposure to different doses of ribavirin 
are given in Table 1.
Body weight gain of adult male rats during 
exposure to different doses of ribavirin – impact 
of treatment duration
Animals repeatedly injected with ribavirin at doses of 
10, 20 and 30 mg/kg/day showed atypical weight gain 
compared to saline-treated ones (Fig. 4A). Kruskal-
Wallis ANOVA revealed a significant impact of riba-
virin treatment on BW gain a day after the seventh 
(H(3.48)=11.13; p<0.05) daily injection, while the in-
fluence of the fourteenth daily injection very slightly 
missed the significance level (H(3.48)=7.37; p=0.06). 
Importantly, Steel’s test revealed that compared to the 
weight gain of the control group, this parameter was 
significantly lower in the group exposed to ribavirin 
at the dose of 30 mg/kg on day 2, and significantly 
lower in groups exposed to ribavirin at doses of 10 
and 30 mg/kg/day on day 8 and on day 15 (Fig. 4B, 
*p<0.05). These data revealed that treatment duration 
was important in assessing the effect of ribavirin on BW.
DISCUSSION
The results of the present study for the first time reveal 
the effects of single (1 day) or repeated (7- and 14-day) 
exposures to low ribavirin doses on psychomotor activ-
ity and body weight gain (as an indicator of energetic 
intake under conditions of controlled utilization) in 
socially undisturbed, group-housed adult male rats. 
These findings indicate that in rats the administration 
of ribavirin at low doses (10, 20 and 30 mg/kg/day, 
corresponding to 100, 200 and 300 mg/day in humans, 
respectively) can influence certain dopamine-mediated 
behaviors in a treatment duration-dependent man-
ner. Although there was no strict regularity between 
changes in novelty-induced and AMPH-induced motor 
activities and BW gain due to repeated application of 
low ribavirin doses, low novelty-induced locomotion 
Table 3. Results of Wilcoxon test
  Locomotion Stereotypy-like movements
Vertical 
activity
 
Ba
se
lin
e
2n
d  d
ay
8th
 d
ay
15
th
 d
ay
Ba
se
lin
e
2n
d  d
ay
8th
 d
ay
15
th
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ay
Ba
se
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e
2n
d  d
ay
8th
 d
ay
15
th
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ay
Saline
40 vs 80 min * * * * * * * * * * * *
40 vs 120 min * * * * * * *   * * *  
Ribavirin 10 mg/kg/day
40 vs 80 min * * * * * * * * *   * *
40 vs 120 min * * * * * * * * *   * *
Ribavirin 20 mg/kg/day
40 vs 80 min * * * * * * * * * *    
40 vs 120 min * * * * * * * * * *    
80 vs 120 min                 *      
Ribavirin 30 mg/kg/day
40 vs 80 min * * * * * * * * * * * *
40 vs 120 min * * * * * * * * * * * *
80 vs 120 min       * *   * * *     *
Saline + AMPH
40 vs 80 min   * *     * *     *    
40 vs 120 min   * * *   * *     * * *
80 vs 120 min   * * *   * *     * *  
Ribavirin 10 mg/kg/day + AMPH
40 vs 80 min   * * *   * * *     *  
40 vs 120 min   * * *   * * *   * * *
80 vs 120 min   * * *   * * *       *
Ribavirin 20 mg/kg/day + AMPH
40 vs 80 min   * * *   * * *   *   *
40 vs 120 min   * * *   * * *   * * *
80 vs 120 min     * *     * *     *  
Ribavirin 30 mg/kg/day + AMPH
40 vs 80 min   * * *   * * *        
40 vs 120 min   * * *   * * *   * *  
80 vs 120 min   * * *   * * *   * * *
*p<0.05; d-amphetamine (AMPH)
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was always accompanied by reduced BW. Moreover, a 
U-shaped dose-response relationship appeared with 
prolonged duration of ribavirin treatment, as for some 
of the examined behaviors the dose-response curve 
was extended to very low ribavirin doses.
Although the undesirable neurobehavioral compli-
cations of prolonged ribavirin therapy have been well 
recognized, an experimental approach that addresses 
the role of the dose and treatment duration on psy-
chomotor functioning has not been undertaken. The 
ribavirin doses used in the current study are far below 
those usually used in humans to treat HCV infections 
[33]. However, low doses of ribavirin have 
already proved to be effective after systemic 
administration in different animal models 
of human autoimmune diseases [41,42] 
and viral infections [43], speaking in favor 
of its therapeutic potential in diseases for 
which it is not primarily intended. Gener-
ally, the consequence of adaptive changes 
in the number of A1 receptors in the brain 
due to their long-term stimulation has been 
described [44, 45].
The extent and timeline profile of riba-
virin action primarily depends on its dose, 
route of administration, treatment dura-
tion, BBB permeability, biodistribution and 
pharmacokinetic properties. Namely, it has 
been reported that 82% of intramuscularly 
administered ribavirin at a dose of 10 mg/
kg was excreted in the urine of rats within 
24 h [12], while the total radioactivity in the 
urine of rats treated intravenously with [14C] 
ribavirin at a dose of 30 mg/kg included 
84% of the initial dose [46]. In the brain of 
rats, the content of ribavirin reached a peak 
at 8 h after intramuscular administration 
of a single dose of 10 mg/kg [12] and was 
detected in different brain areas (cerebellum, 
olfactory bulb, cerebral cortex, basal ganglia 
and hippocampus) 20 min after intravenous 
or nasal application of the same ribavirin 
dose [47]. This is supported by the find-
ing of a previous study that pretreatment 
with ribavirin at doses of 20 and 30 mg/
kg significantly decreased hyperlocomo-
tor activity induced by AMPH (1.5 mg/kg, 
i.p.) application 20 min later [20]. Given 
this data, the lack of an effect of a single ribavirin 
treatment on spontaneous and AMPH-induced mo-
tor behavior 24 h later can be explained by its rapid 
elimination from the body, and/or by its decreasing 
concentration in the brain to a level that cannot cause 
observable behavioral changes.
Importantly, 24 h after 7 i.p. administrations of riba-
virin (one per day), dose-specific and opposite changes 
in novelty-induced and AMPH-induced motor activities 
were observed, pointing to overall adaptations within 
the novelty- and AMPH-responsive brain regions due 
Fig. 3. The influence of single, 7- and 14-day treatments with ribavirin at low doses 
(10, 20 and 30 mg/kg/day, i.p.) on d-amphetamine (AMPH)-induced locomo-
tion (A), stereotypy-like activity (B) and vertical activity (C) of rats. The AMPH 
challenge (1.5 mg/kg, i.p.) was performed on the 2nd day (a day after the first 
once-a-day i.p. injection), on the 8th day (a day after the seventh once-a-day i.p. 
injection) and on the 15th day (a day after the fourteenth once-a-day i.p. injection) 
of the experiment. Immediately after the AMPH injection, the animals’ behavior 
was monitored in an open field arena for 120 min. Each time point represents 
the mean±SEM (n=6). *p<0.05 indicates significant differences compared to the 
control (saline-injected) group (Steel’s test).
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to systemic ribavirin administration. Namely, common 
to these stimuli is that they are dopamine-mediated 
[21,30,31]. Our findings indicate that the outcome 
of the 7-day ribavirin pretreatment depended on the 
neurochemical peculiarities of the subsequent stimu-
lus: AMPH targets the dopamine transporter (DAT) 
at mesolimbic/mesostriatal dopaminergic terminals 
[37,48], while novelty-induced motor activity strongly 
depends on excitatory glutamatergic inputs to the ventral 
tegmental area (VTA) and consequential elevation of 
mesolimbic dopaminergic transmission [31]. It has been 
shown that after exposure to the novel stimulus, the NAc 
dopamine level remained elevated for the entire 120 min 
period and was accompanied by increased motor activity 
[31]. It has also been documented that stimulation of 
A1 receptor activity in the VTA negatively influenced 
motor activation [49]. In light of these findings and 
considering the data obtained in our study it could be 
assumed that the 7-day application of ribavirin, which 
has a moderate affinity for A1 receptors [15], could 
influence VTA activity regulation. Consequently, the 
magnitude of VTA stimulation by novelty was lower 
in animals exposed to (certain) low ribavirin doses as 
novel stimuli lost the novelty faster in ribavirin-exposed 
than in the control group. The AMPH-induced motor 
behavior suggested that DAT-mediated dopamine release 
from dopaminergic terminals was not affected; however, 
this finding needs additional examination with other 
drugs that act through DAT.
All natural rewarding stimuli, including food, act 
through the activation of midbrain dopaminergic neu-
rons, increasing accumbal/striatal levels of dopamine 
[50-52]. It has been shown that the regulated release 
of dopamine is important for sustained feeding [53] 
and that consumption of food is related to dopamine 
transmission in several regions of the striatum (in the 
caudate putamen for response to the caloric value of 
food and regular feeding, in the NAc for the rewarding 
aspect of feeding [52]). Overactivity of A1 receptors, 
in addition to locomotor activity decrease, also pro-
duces hypophagia [51]. It has also been shown that 
stimulation of the A1 receptor inhibits ghrelin release 
from the stomach (colocalization of ghrelin and A1 
receptor immunoreactivity in the gastric nerve fibers 
are observed). Ghrelin is a hormone that crosses the 
BBB and stimulates dopamine signaling in the NAc [54, 
55]. In our experiment, 7 days of ribavirin treatment 
(10 and 30 mg/kg/day) was, in addition to a decrease 
in novelty-induced motor activity, accompanied by a 
slight, but significant reduction in BW gain in treated 
animals compared to controls. This supports the as-
sumption that 7-day ribavirin administration could 
provoke peculiar changes in the regulation of midbrain 
dopaminergic system activity, thus influencing/dimin-
ishing physiological (novelty-induced motor activity 
and food-directed behavior), but not the pharmaco-
logical (AMPH-induced motor activity) responses 
that depend on it. We have to accentuate that single 
housing of animals and direct measurement of food 
consumption were not performed in our experiment 
in order to avoid stress reaction and behavioral con-
sequences of social isolation [56] that could interfere 
with the parameters of interest.
Fig. 4. The influence of ribavirin applied at low doses (10, 20 and 
30 mg/kg/day, i.p.) for 14 days on the body weight (A) and body 
weight gain (B) of rats. The data obtained in Experiment 1 and 
Experiment 2 (14-day treatment) were summarized to obtain 
the total number of 12 animals per group/dose and to calculate 
the parameters of interest. Body weight gain was calculated by 
subtracting the weight of the rat measured at the beginning of the 
experiment from that measured at the day of behavioral testing. 
Each time point represents the mean (n=12). *p<0.05 indicates 
significant differences compared to the control (saline-injected) 
group (Steel’s test).
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A decrease in BW gain accompanied by the nov-
elty-provoked decrease in locomotion was detectable 
after 14 days of ribavirin application. Although the 
pattern/extent of changes indicates that the effect was 
decreasing, the U-shaped dose-response relationship 
was still evident, accentuating the cumulative effects 
of small ribavirin doses (10 and 30 mg/kg/day). The 
effect of treatment with 20 mg/kg/day on basal and 
AMPH-induced motor activities indicated that at this 
dose ribavirin had an atypical mechanism of action, 
which was not seen with the tested lower and higher 
doses. In clinical usage, the dose of 200 mg/day (cor-
responding to 20 mg/kg/day in rats) is recommended 
for renal-impaired HCV patients [33].
Due to the relatively short duration of treatment, 
we were not able to fully define whether prolonged 
ribavirin application could minimize the effect of small 
ribavirin doses on novelty-induced psychomotor activ-
ity and BW gain as the consequence of the allostatic 
process (i.e. the dynamic biobehavioral adaptation in 
response to external stimulation/treatment; [57]). In 
that sense, the presence of changes in motor activity 
after d-AMPH challenge also suggested that physi-
ological readjustment caused by a 14-day ribavirin ap-
plication tends to be outside the homeostatic range, 
introducing the system into a state that might require 
more specific pharmacological stimulation to detect 
any irregularities in its functioning. Therapeutic appli-
cation of ribavirin in real conditions is a multi-month 
[2] procedure, but in our experimental paradigm this 
was not appropriate because i.p. treatment is stressful 
for animals [58]. Thus, the influence of the repeated 
i.p. injection protocol used in our study should not 
be neglected, especially considering the fact that in 
the control group the absence of a time-dependent 
decrease in stereotypy-like and vertical activities was 
noticed after the 14-day saline injections, which was 
not the case in 1-day and 7-day injection protocols. 
Importantly, in animals exposed to 10 and 30 mg/kg/
day, examination regularity was preserved after the 
14 days of ribavirin injections, suggesting a protective 
role of repeatedly used low ribavirin doses in chronic 
mild stress-induced responses, which deserves to be 
additionally examined. Behavior of the group exposed 
to 20 mg/kg/day of ribavirin was control-like, indicating 
once again that at this dose, ribavirin has an atypical 
mechanism of action. The role of A1 adenosine re-
ceptors is extensively implicated in defense reactions 
and in the brain’s response to stress [59]. Given that 
ribavirin has affinity for A1 receptors [15], its involve-
ment in the abovementioned stress response seems 
quite acceptable.
The question that remains unanswered is the nature 
of motor activity increase induced in the experimental 
groups by d-AMPH injection compared to the saline 
injection. Such analysis requires an additional 72 rats, 
with most likely no impact on the accuracy of other 
data. Therefore, in our attempt to minimize the number 
of rats used, we chose to omit these groups. Neverthe-
less, the absence of peculiarities in the psychomotor re-
sponse to strong/pharmacological stimulation does not 
mean that fine physiological regulation is undisturbed 
by prolonged ribavirin treatment. These experiments 
should be considered and examined in depth in further 
studies, to provide concrete data on the neurochemical 
and molecular bases of this phenomenon.
CONCLUSIONS
The findings of this study are a valuable contribution to 
an understanding of the psychomotor and physiologi-
cal response to low ribavirin doses in a rodent model, 
with reference to treatment duration. Although we 
did not observe strict regularity between the changes 
in novelty- and AMPH-induced motor activities and 
BW gain due to repeated application of low ribavirin 
doses, low novelty-induced locomotion was always ac-
companied by reduced BW gain. The observed effects 
were discrete, as is appropriate for an agent that has not 
been primarily assessed as neuroactive, but should not 
be neglected as they accentuate potential undesirable 
manifestations of application of low ribavirin doses 
during the first days and weeks of treatment. By ac-
centuating the U-shaped dose-response relationship 
related to prolonged duration of ribavirin treatment, 
this study opens up the issue of potential undesirable/
unexpected effects of low ribavirin doses.
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